ClinicalTrials.gg
Not yet recruitingNCT07945535NEUROBOSTUpdated Nov 18, 2026

Mechanisms Underlying the Greater Efficacy of Robot-Assisted Gait Rehabilitation Versus Conventional Therapy Combined With Botulinum Toxin Injection of the Triceps Surae in Individuals With Chronic Post-Stroke Impairments

An interventional study of Combined Functional Near-infrared Spectroscopy and Electroencephalography System and MRI Imaging in Stroke, Stroke (6 Months or More After Onset) and Stroke Gait Rehabilitation, sponsored by Aix Marseille Université. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aix Marseille Université · Not applicable, Interventional, and Basic science

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 545 studies in Stroke with a site in France — 143 open to participants now, 162 under way, 12 of them phase 3. Stroke · France.

Planned enrollment
233rd of 370
40 · median 64
Started
2026
with 31 others
No phase
277 of 545
94 open now
Primary completion
2029-06
later than 146 of 161 live
Registered
545th of 545
by date

Among the 545 studies in Stroke with a site in France, this one is the 233rd largest by planned enrollment of the 370 interventional ones that give a count, is one of 32 that started in 2026, is one of 277 with no phase, reaches primary completion later than 146 of the 161 other live ones, and was the 545th registered.

Stroke

8,279 studies on the registry are indexed under Stroke; 2,067 are open to participants now.

Browse Stroke studies →

Open to participants now

143 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 545 studies in Stroke with a site in France, or all of them as a file.
02

Study summary

Stroke is a leading cause of long-term disability in adults. Many people who have had a stroke continue to experience difficulty walking because of muscle weakness and spasticity, which can limit their mobility and quality of life.

Botulinum toxin injections are commonly used to reduce spasticity in specific muscles, such as the calf muscles. Rehabilitation is then used to improve walking ability. Robot-assisted gait rehabilitation allows patients to practice walking intensively and repeatedly, with assistance adjusted to their needs. Previous research from our team has shown that robot-assisted gait rehabilitation may improve walking ability more than conventional physical therapy when combined with botulinum toxin injections.

The purpose of this study is to better understand why robot-assisted gait rehabilitation may be more effective than conventional gait rehabilitation after botulinum toxin treatment in people with chronic stroke. The study will examine changes in walking patterns, muscle activity, and brain activity during and after rehabilitation. Brain activity and brain connections will be assessed using non-invasive methods, including functional near-infrared spectroscopy (fNIRS), electroencephalography (EEG), and magnetic resonance imaging (MRI).

The study may help identify how the brain and body adapt to rehabilitation and may contribute to developing more personalized rehabilitation programs for people living with long-term effects of stroke.

Read the detailed description

Stroke is a major cause of acquired motor disability in adults. In the chronic phase after stroke, persistent motor impairment is frequently associated with spastic paresis, altered motor control, and maladaptive or compensatory reorganization of the central nervous system. Spasticity may contribute substantially to gait impairment and reduced mobility, thereby affecting functional independence and quality of life.

Botulinum toxin type A (BoNT-A) is an established treatment for focal spasticity after stroke. Intramuscular injection into the triceps surae reduces excessive muscle activity through its action at the neuromuscular junction and can temporarily improve the mechanical conditions for walking. In addition to these peripheral effects, BoNT-A may also indirectly influence central motor networks by modifying proprioceptive and afferent sensory input, potentially promoting cortical reorganization.

Following BoNT-A injection, intensive rehabilitation is required to optimize functional recovery. Robot-assisted gait rehabilitation provides a means of delivering intensive, repetitive, task-specific gait practice, with partial body-weight support and adjustable motor assistance. This approach may allow patients to perform a greater number of gait cycles and to train at higher walking speeds than conventional gait therapy. Previous studies have suggested that robot-assisted gait rehabilitation may improve gait performance, propulsion, gait symmetry, and motor coordination. In a previous study conducted by our research team, robot-assisted gait rehabilitation performed after BoNT-A injection into the triceps surae resulted in a significantly greater improvement in 6-minute walk distance than conventional gait rehabilitation.

The present study aims to investigate the neurophysiological and biomechanical mechanisms underlying the potentially greater benefit of robot-assisted gait rehabilitation compared with conventional gait rehabilitation following BoNT-A treatment in individuals with chronic stroke.

The study will characterize changes in gait performance and gait biomechanics, including spatiotemporal parameters, lower-limb joint kinematics, ground reaction forces, propulsion, and muscle activation patterns. These measurements will be used to determine whether specific changes in gait mechanics and neuromuscular coordination are associated with the greater improvement observed following robot-assisted rehabilitation.

In parallel, the study will investigate changes in brain activity and functional organization associated with rehabilitation. Functional near-infrared spectroscopy (fNIRS) will be used to assess cortical activation during walking. Electroencephalography (EEG) will be used to characterize cortical electrical activity and functional connectivity, with particular attention to changes in frontoparietal and motor networks. Resting-state functional magnetic resonance imaging (fMRI) and diffusion MRI will be used to assess functional and structural brain connectivity, respectively, as well as lesion characteristics and the organization of motor networks.

A particular focus will be placed on changes in the lateralization and organization of motor cortical activity following rehabilitation. The study will test the hypothesis that robot-assisted gait rehabilitation induces more effective neuroplastic adaptations than conventional gait rehabilitation after BoNT-A treatment. These adaptations are expected to involve a shift toward more efficient recruitment and functional organization of ipsilesional motor regions, together with changes in interhemispheric and network-level connectivity.

The study will also investigate whether central effects of BoNT-A can be detected through changes in cortical activity, including modifications of ipsilesional posterior parietal cortex activity previously reported after BoNT-A treatment.

By combining complementary neurophysiological, neuroimaging, biomechanical, and clinical measures, the study aims to identify mechanisms associated with improved walking recovery after BoNT-A combined with robot-assisted gait rehabilitation. An additional objective is to identify quantitative biomarkers that may help predict which individuals are most likely to benefit from this rehabilitation strategy and, ultimately, contribute to more individualized rehabilitation approaches for people with chronic post-stroke motor impairment.

03

Conditions studied

  • Stroke
  • Stroke (6 Months or More After Onset)
  • Stroke Gait Rehabilitation

Keywords

  • Chronic stroke
  • Post-stroke rehabilitation
  • Hemiparesis
  • Spasticity
  • Gait impairment
  • Robot-assisted gait training
  • Botulinum toxin type A
  • Neuroplasticity
  • Motor recovery
  • Brain connectivity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with hemiparesis.
  • Affiliated with a national or public health insurance system.
  • Able and willing to provide written after receiving information about the purpose, procedures, and potential risks of the study.
  • At least 6 months after a unilateral stroke.
  • Presence of triceps surae spasticity causing impaired gait and treatment with botulinum toxin type A (BoNT-A) as part of routine care, with a stable dose for at least 2 treatment cycles.
  • Able to walk for 6 minutes; walking speed \<0.8 m/s on the 10-Meter Walk Test.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment preventing the participant from providing .
  • Triceps surae spasticity >3/5 on the Modified Ashworth Scale.
  • Any to physical exercise, robot-assisted gait rehabilitation using the Lokomat, or MRI.
  • Claustrophobia or fear of confined spaces.
  • Individuals deprived of liberty by judicial or administrative decision, or under legal guardianship.
  • Inability to complete all study procedures.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  • Concurrent participation in another research study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Robot-Assisted Gait Rehabilitation

    Participants receive robot-assisted gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of intensive, repetitive gait training using a robotic device, with adjustable assistance and body-weight support as appropriate.

    Other: Combined Functional Near-infrared Spectroscopy and Electroencephalography System · Other: MRI Imaging · Behavioral: 6-Minute Walk Test · Behavioral: Muscle Strength Scale · Behavioral: Berg Balance Scale

  • Active comparator
    Conventional Gait Rehabilitation

    Participants receive conventional gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of therapist-guided gait training and conventional physical therapy according to standard clinical practice.

    Other: Combined Functional Near-infrared Spectroscopy and Electroencephalography System · Other: MRI Imaging · Behavioral: 6-Minute Walk Test · Behavioral: Muscle Strength Scale · Behavioral: Berg Balance Scale

Interventions

  • OtherCombined Functional Near-infrared Spectroscopy and Electroencephalography System

    Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.

    Also known as: EEG, fNIRS

  • OtherMRI Imaging

    The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.

    Also known as: MRI, Magnetic resonance imaging

  • Behavioral6-Minute Walk Test

    Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.

    Also known as: 6MWT

  • BehavioralMuscle Strength Scale

    Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.

    Also known as: MRC Scale

  • BehavioralBerg Balance Scale

    Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.

    Also known as: BBS

06

What researchers measure

Primary outcomes

  1. Difference in the Lateralization Index of Nodal Degree in the Paracentral Lobules

    The primary outcome measure is the between-group difference in the organization of motor functional brain networks following botulinum toxin type A (BoNT-A) treatment of spasticity in the triceps surae, comparing robot-assisted gait rehabilitation with conventional gait rehabilitation. At rest, functional brain network organization will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary resting-state parameter will be the lateralization index (Lik) of nodal degree (k) in the paracentral lobules ipsilateral and contralateral to the stroke lesion. The Lik will be used to quantify the relative distribution of nodal connectivity between the two hemispheres.

    Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

  2. Difference in the Lateralization Index of Activation in the Sensorimotor Cortex Derived From fNIRS Data

    The lateralization index of cortical activation in the sensorimotor cortex will be calculated from functional near-infrared spectroscopy (fNIRS) data collected during walking. The outcome measure will assess the difference in the lateralization of sensorimotor cortical activation between robot-assisted gait rehabilitation and conventional gait rehabilitation following botulinum toxin type A treatment of spasticity in the triceps surae. Higher or lower lateralization index values will indicate a relative predominance of activation in one cerebral hemisphere.

    Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Secondary outcomes

  1. Lateralization of Brain Activation in Locomotor-Related Cortical Areas During Walking

    The lateralization of brain activation in cortical areas involved in locomotion, including the prefrontal cortex (PFC), premotor cortex (PMC), and supplementary motor area (SMA), will be assessed during walking using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Differences in the lateralization of cortical activation between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups will be evaluated following botulinum toxin type A treatment of spasticity in the triceps surae.

    Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

  2. Change in Resting-State Activity of the Ipsilesional Posterior Parietal Cortex

    Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in activity of the posterior parietal cortex ipsilateral to the stroke lesion. The change in resting-state activity will be compared between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups following botulinum toxin type A treatment of spasticity in the triceps surae.

    Time frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

07

Study locations

1 site
  • UGECAM IUR Valmante Sud
    Marseille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2029, 30 months later.

Of 3,120 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 30 months is above that.

Counting every sponsor, half of 3,264 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945535
Lead sponsor
Aix Marseille Université
Collaborators
UGECAM PACA et Corse
Responsible party
COTINAT Maeva (Principal Investigator, Aix Marseille Université) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Maëva COTINAT, MD
Contact
Maeva.cotinat@ap-hm.fr
+33 4 91 74 20 00
Laurent BENSOUSSAN, MD
Contact
laurent.bensoussan@ap-hm.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion